stockrow
Friday 6 November 2026
Export EVGN’s income statement to Excel — free account
Evogene Ltd.
EVGN Healthcare Biotechnology
Evogene Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, down 54.7% from fiscal 2024.
- Revenue
- −35.0%
- EPS
- +77.4%
- Free cash flow
- +17.7%
Quarter to June 2026, against a year earlier
0.28
0.05
−15.15%
Follow EVGN
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
2 | 3 | 3 | 4 | 3 | 3 | 4 | 4 | 3 | 3 |
Altman Z-Score |
7.95 | 3.80 | 0.29 | (1.19) | 1.37 | (1.25) | (5.89) | (6.98) | (10.63) | (20.48) |
P/S ratio |
19.76 | 26.35 | 29.19 | 51.99 | 127.26 | 71.30 | 17.84 | 7.09 | 1.25 | 2.25 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
11.55 | 7.80 | 1.95 | 0.54 | (2.63) | (2.10) | (11.33) | (15.04) | (24.48) | (45.11) |
Beneish M-Score |
(3.38) | (2.69) | (2.76) | 344.94 | (2.53) | (2.29) | (3.07) | (1.38) | (1.87) | — |
P/Operating CF |
(30.54) | (24.98) | 12.77 | (8.40) | (19.26) | (8.20) | (13.24) | (6.75) | (2.34) | (3.22) |
P/B ratio |
1.48 | 1.28 | 1.01 | 0.65 | 2.33 | 1.05 | 0.86 | 1.39 | 0.72 | 0.72 |
Price to Tangible BV |
1.48 | 1.28 | 1.01 | 0.91 | 3.25 | 1.38 | 1.45 | 2.58 | 4.03 | 433.07 |
EV/Sales |
6.28 | 5.13 | (1.99) | (10.27) | 80.88 | 13.38 | (3.27) | 1.58 | (0.55) | (1.12) |
EV/EBITDA |
0.00 | 0.00 | 0.18 | 0.42 | 0.00 | 0.00 | 0.22 | 0.00 | 0.27 | 0.37 |
EV/Operating CF |
(3.52) | (1.09) | 0.42 | 0.44 | (4.31) | (0.50) | 0.23 | (0.41) | 0.24 | 0.32 |
EV/FCF |
(3.29) | (1.05) | 0.42 | 0.42 | (4.17) | (0.49) | 0.22 | (0.40) | 0.23 | 0.32 |
Quick Ratio |
17.13 | 15.61 | 10.22 | 8.53 | 5.36 | 8.25 | 6.61 | 4.95 | 0.99 | 4.32 |
Current Ratio |
17.13 | 15.61 | 10.22 | 8.53 | 5.36 | 8.27 | 6.71 | 4.96 | 1.15 | 4.54 |
Net Debt/EBITDA |
4.69 | 3.62 | 3.03 | 2.55 | 2.18 | 1.88 | 1.45 | 1.30 | 0.90 | 1.12 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.06 | 0.04 | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | 0.11 | 0.19 | 0.13 |
Operating CF/Net income |
0.60 | 0.76 | 0.73 | 0.98 | 0.83 | 0.89 | 0.89 | 0.90 | 1.20 | 1.59 |
Capex/Depreciation |
(0.35) | (0.28) | (0.19) | (0.32) | (0.25) | (0.38) | (0.45) | (0.29) | (0.33) | (0.02) |
Interest Coverage |
(23.67) | (21.84) | (9.06) | (38.14) | (8.41) | (21.89) | (8.09) | (27.47) | (5.60) | (7.26) |
| (20.51%) | (26.60%) | (34.69%) | (32.78%) | (39.92%) | (46.21%) | (54.25%) | (75.24%) | (75.75%) | (63.29%) | |
| (18.79%) | (24.01%) | (30.46%) | (27.85%) | (32.63%) | (37.50%) | (40.23%) | (44.54%) | (36.24%) | (28.33%) | |
ROIC |
0.00% | 0.00% | 0.00% | (99.16%) | (179.23%) | (202.49%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(21.59%) | (28.58%) | (38.99%) | (39.49%) | (52.86%) | (53.36%) | (76.93%) | (79.65%) | (350.89%) | (65.27%) |
Average Days of Receivables |
74.34 | 111.84 | 213.32 | 1,042.65 | 1,261.36 | 1,150.73 | 398.78 | 215.51 | 135.30 | 178.28 |
Research and Development Expense of Revenue |
250.84% | 502.43% | 840.64% | 2,097.08% | 1,662.21% | 2,271.51% | 1,241.31% | 368.39% | 147.00% | 207.47% |
Selling, General and Administrative Expense of Revenue |
59.46% | 112.69% | 201.14% | 500.00% | 511.63% | 1,074.30% | 621.79% | 171.61% | 105.46% | 149.55% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.24 | 0.22 | 0.20 | 0.25 | 0.26 | 0.31 | 0.00 |
Share Based Compensation of Revenue |
45.00% | 66.37% | 99.08% | 209.56% | 393.94% | 280.54% | 70.81% | 33.28% | 14.60% | 16.97% |
Graham Net Nets |
0.63 | 0.72 | 0.92 | 0.97 | 0.28 | 0.66 | 0.55 | 0.30 | (0.32) | 0.87 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(15.16%) | (23.34%) | (41.41%) | (46.71%) | (17.45%) | (42.07%) | (88.28%) | (60.85%) | (166.31%) | (106.36%) |
Free Cash Flow Yield |
(9.67%) | (18.54%) | (16.42%) | (47.43%) | (15.26%) | (38.55%) | (83.17%) | (55.88%) | (190.70%) | (156.55%) |
Revenue per Share |
2.57 | 1.32 | 0.68 | 0.29 | 0.37 | 0.23 | 0.41 | 1.23 | 1.49 | 0.49 |
Operating CF per Share |
(4.60) | (6.20) | (5.89) | (6.86) | (6.93) | (6.11) | (5.75) | (4.70) | (3.46) | (1.71) |
Capex per Share |
(0.32) | (0.23) | (0.15) | (0.35) | (0.24) | (0.21) | (0.28) | (0.17) | (0.11) | (0.01) |
Free Cash Flow per Share |
(4.91) | (6.43) | (6.03) | (7.21) | (7.17) | (6.32) | (6.03) | (4.87) | (3.57) | (1.72) |
Cash per Share |
34.65 | 27.95 | 21.15 | 18.20 | 17.13 | 13.32 | 8.58 | 6.77 | 2.69 | 1.65 |
Shareholders Equity per Share |
34.31 | 27.02 | 19.53 | 23.38 | 20.20 | 15.69 | 8.44 | 6.25 | 2.60 | 1.52 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
34.31 | 27.02 | 19.53 | 23.38 | 20.20 | 15.69 | 8.44 | 6.25 | 2.60 | 1.52 |
Free Cash Flow |
(12.50) | (16.52) | (15.53) | (18.57) | (20.20) | (25.56) | (24.85) | (22.34) | (20.32) | (13.56) |
Working Capital |
84.27 | 68.13 | 50.06 | 43.28 | 42.15 | 50.01 | 32.13 | 27.53 | 2.89 | 12.19 |
Capital Expenditures |
(0.80) | (0.59) | (0.37) | (0.90) | (0.68) | (0.85) | (1.17) | (0.76) | (0.62) | (0.06) |
Net Current Asset Value |
80.79 | 64.57 | 47.10 | 37.88 | 36.79 | 44.01 | 16.42 | 12.05 | (3.44) | 7.56 |
EV/EBIT |
0.00 | 0.00 | 0.17 | 0.37 | 0.00 | 0.00 | 0.20 | 0.00 | 0.25 | 0.31 |
Capex to Sales |
0.12 | 0.17 | 0.21 | 1.20 | 0.66 | 0.91 | 0.70 | 0.13 | 0.07 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.35 | 0.45 | 0.63 | 1.07 | 1.32 | 1.08 | 1.03 | 1.06 | 1.03 | 3.04 |
Cash ROIC |
(7.12%) | (11.70%) | (14.83%) | (17.34%) | (19.21%) | (21.80%) | (35.43%) | (37.38%) | (67.39%) | (54.32%) |
Accounts Receivable Turnover |
2.60 | 2.86 | 1.70 | 0.47 | 0.36 | 0.29 | 0.70 | 2.19 | 2.62 | 1.53 |
Accounts Payable Turnover |
3.64 | 2.33 | 1.37 | 0.33 | 0.62 | 0.66 | 0.73 | 1.20 | 1.58 | 4.39 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.76 | 5.27 | 2.51 | 4.04 |
Average Days of Payables |
86.09 | 142.41 | 255.15 | 1,093.91 | 548.77 | 696.21 | 416.00 | 385.06 | 188.33 | 56.97 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.78 | 227.27 | 16.39 | 278.96 | 18.72 |
Average Receivables |
2.52 | 1.18 | 1.03 | 1.59 | 2.87 | 3.26 | 2.38 | 2.58 | 3.24 | 2.52 |
Average Payables |
1.55 | 1.22 | 1.06 | 1.01 | 0.93 | 1.16 | 1.25 | 1.41 | 1.51 | 0.93 |
Average Inventory |
— | — | — | — | — | — | 0.33 | 0.32 | 0.95 | 1.01 |
Average Assets |
104.29 | 86.79 | 68.15 | 65.03 | 71.64 | 74.11 | 66.22 | 53.61 | 45.48 | 29.96 |
Average Common Equity |
95.52 | 78.33 | 59.84 | 55.26 | 58.55 | 60.15 | 49.11 | 31.74 | 21.76 | 13.41 |
Columns are period end dates · fundamentals updated 26 Oct 2026